{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:25:48Z","timestamp":1788193548763,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jaad.2023.01.043","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T02:46:48Z","timestamp":1676429208000},"page":"309-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Practical management of ocular surface disease in patients with atopic dermatitis, with a focus on conjunctivitis: A review"],"prefix":"10.1016","volume":"89","author":[{"given":"Vivian Y.","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Siegfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Kraff-Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Beckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8 suppl","key":"10.1016\/j.jaad.2023.01.043_bib1","first-page":"S115","article-title":"Overview of atopic dermatitis","volume":"23","author":"Avena-Woods","year":"2017","journal-title":"Am J Manag Care"},{"issue":"4","key":"10.1016\/j.jaad.2023.01.043_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/09546634.2019.1659480","article-title":"Association between atopic dermatitis and conjunctivitis in adults: a population-based study in the United States","volume":"32","author":"Wu","year":"2021","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.jaad.2023.01.043_bib3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5114\/ada.2018.79445","article-title":"Ophthalmic manifestations of\u00a0atopic\u00a0dermatitis","volume":"37","author":"Pietruszy\u0144ska","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"issue":"6","key":"10.1016\/j.jaad.2023.01.043_bib4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/cea.14127","article-title":"Ocular surface disease is common in moderate-to-severe atopic dermatitis patients","volume":"52","author":"Achten","year":"2022","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.jaad.2023.01.043_bib5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/jdv.17832","article-title":"Factors associated with ocular surface disease and severity in adults with atopic dermatitis: a nationwide survey","volume":"36","author":"Ronnstad","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2023.01.043_bib6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/1203475417743233","article-title":"Diagnosis and management of conjunctivitis for the dermatologist","volume":"22","author":"Gooderham","year":"2018","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"10.1016\/j.jaad.2023.01.043_bib7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/ICU.0000000000000532","article-title":"Ocular involvement in atopic disease: a review","volume":"29","author":"Patel","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"10.1016\/j.jaad.2023.01.043_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40257-020-00577-1","article-title":"Conjunctivitis in dupilumab clinical trials for adolescents with atopic dermatitis or asthma","volume":"22","author":"Bansal","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.01.043_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.18502\/jovr.v15i3.7456","article-title":"Conjunctivitis: a systematic review","volume":"15","author":"Azari","year":"2020","journal-title":"J Ophthalmic Vis Res"},{"issue":"10","key":"10.1016\/j.jaad.2023.01.043_bib10","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2023.01.043_bib11","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/jdv.15608","article-title":"Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion","volume":"33","author":"Thyssen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2023.01.043_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.01.043_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40268-019-00288-x","article-title":"A clinician's guide to the recognition and management of dupilumab-associated conjunctivitis","volume":"19","author":"Agnihotri","year":"2019","journal-title":"Drugs R D"},{"issue":"3","key":"10.1016\/j.jaad.2023.01.043_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.01.043_bib15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjd.20810","article-title":"Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials","volume":"186","author":"Wollenberg","year":"2022","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.01.043_bib16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.alit.2020.06.004","article-title":"Epidemiological aspects of allergic conjunctivitis","volume":"69","author":"Miyazaki","year":"2020","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.jaad.2023.01.043_bib17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","article-title":"Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis","volume":"77","author":"Thyssen","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.01.043_bib18","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jtos.2020.03.007","article-title":"Giant papillary conjunctivitis: a review","volume":"18","author":"Kenny","year":"2020","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jaad.2023.01.043_bib19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamaophthalmol.2013.6277","article-title":"Association between atopy and herpetic eye disease: results from the pacific ocular inflammation study","volume":"132","author":"Borkar","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.jaad.2023.01.043_bib20","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/ACI.0b013e32833e16e4","article-title":"Atopic keratoconjunctivitis and atopic dermatitis","volume":"10","author":"Guglielmetti","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2023.01.043_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1203475420982553","article-title":"Inhibition of IL-13: a new pathway for atopic dermatitis [formula: see text]","volume":"25","author":"Ratnarajah","year":"2021","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"10.1016\/j.jaad.2023.01.043_bib22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/ACI.0b013e32830edbcb","article-title":"Immune regulatory mechanisms in allergic conjunctivitis: insights from mouse models","volume":"8","author":"Niederkorn","year":"2008","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2023.01.043_bib23","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jaad.2023.01.043_bib24","first-page":"2992","article-title":"IL-4 and IL-13 regulation of ICAM-1 expression and eosinophil recruitment in Onchocerca volvulus keratitis","volume":"43","author":"Berger","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.jaad.2023.01.043_bib25","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.ajpath.2020.02.004","article-title":"Sympathetic nerves positively regulate eosinophil-driven allergic conjunctivitis via alpha1-adrenergic receptor signaling","volume":"190","author":"Liu","year":"2020","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.jaad.2023.01.043_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.iac.2010.06.004","article-title":"Atopic dermatitis and keratoconjunctivitis","volume":"30","author":"Bielory","year":"2010","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"10.1016\/j.jaad.2023.01.043_bib27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2023.01.043_bib28","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1111\/all.15064","article-title":"Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1\/T17 cytokines: a case series study","volume":"76","author":"Bakker","year":"2021","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.jaad.2023.01.043_bib29","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jaad.2019.12.039","article-title":"Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting","volume":"82","author":"Uchida","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.01.043_bib30","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.01.043_bib31","doi-asserted-by":"crossref","first-page":"12162","DOI":"10.1038\/s41598-018-30002-x","article-title":"Context-dependent regulation of conjunctival goblet cell function by allergic mediators","volume":"8","author":"Garcia-Posadas","year":"2018","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jaad.2023.01.043_bib32","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1111\/all.15326","article-title":"IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in\u00a0vitro","volume":"77","author":"Hansen","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2023.01.043_bib33","series-title":"4th Inflammatory Skin Disease Summit","article-title":"IL-13 and IL-4 Promote Proliferation and mRNA Expression of MUC2 and MUC5AC in Primary Human Conjunctival Goblet Cells","author":"Tollenaere","year":"2021"},{"issue":"6","key":"10.1016\/j.jaad.2023.01.043_bib34","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/j.jaad.2021.01.043","article-title":"Dermatology-ophthalmology collaborations are needed in dupilumab-associated ocular events","volume":"84","author":"Thompson","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.01.043_bib35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jaad.2020.11.037","article-title":"Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: a systematic review and meta-analysis","volume":"85","author":"Ravn","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.01.043_bib36","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/09286586.2021.1971262","article-title":"A systematic review of clinical practice guidelines for infectious and non-infectious conjunctivitis","volume":"29","author":"Chan","year":"2022","journal-title":"Ophthalmic Epidemiol"},{"issue":"9","key":"10.1016\/j.jaad.2023.01.043_bib37","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1111\/jdv.17210","article-title":"Dupilumab and conjunctivitis: a case series of twenty patients","volume":"35","author":"Calabrese","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2023.01.043_bib38","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jaad.2023.01.043_bib39","series-title":"US Pharmacist","article-title":"Nonprescription products for minor eye conditions","author":"Pray","year":"2011"},{"issue":"3","key":"10.1016\/j.jaad.2023.01.043_bib40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/jop.2019.0060","article-title":"The\u00a0immunological Basis of dry eye disease and current topical treatment options","volume":"36","author":"Periman","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jaad.2023.01.043_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2500\/aap.2015.36.3827","article-title":"Central serous chorioretinopathy secondary to corticosteroids in patients with atopic disease","volume":"36","author":"Ricketti","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaad.2023.01.043_bib42","series-title":"Revolutionizing Atopic Dermatitis virtual (RAD virtual)","article-title":"Efficacy and Safety of Tralokinumab Plus Topical Corticosteroids in Patients with Severe Atopic Dermatitis and Prior History of Dupilumab Treatment: a Post Hoc Subgroup Analysis from ECZTRA 7 Trial","author":"Gutermuth","year":"2021"},{"issue":"5","key":"10.1016\/j.jaad.2023.01.043_bib43","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.01.043_bib44","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.01.043_bib45","series-title":"Fall Clincal Dermatology Conference 40th anniversary","article-title":"Efficacy and Safety of Tralokinumab in Adolescents with Moderate-To-Severe Atopic Dermatitis: results of the Phase 3 ECZTRA 6 trial","author":"Paller","year":"2021"},{"issue":"1","key":"10.1016\/j.jaad.2023.01.043_bib46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.01.043_bib47","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","volume":"94","author":"Thaci","year":"2019","journal-title":"J Dermatol Sci"},{"issue":"11","key":"10.1016\/j.jaad.2023.01.043_bib48","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Mennini","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2023.01.043_bib49","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjd.20706","article-title":"New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab","volume":"186","author":"Bortoluzzi","year":"2022","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.01.043_bib50","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/ICO.0000000000002461","article-title":"Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up","volume":"40","author":"Bohner","year":"2021","journal-title":"Cornea"},{"issue":"12","key":"10.1016\/j.jaad.2023.01.043_bib51","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jamadermatol.2018.3427","article-title":"Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management","volume":"154","author":"Levine","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.01.043_bib52","series-title":"Making Eye Health a Population Health Imperative: Vision for Tomorrow","year":"2016"},{"issue":"2","key":"10.1016\/j.jaad.2023.01.043_bib53","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ophtha.2016.11.003","article-title":"Vision and public health: framing a purpose for Our work","volume":"124","author":"Lee","year":"2017","journal-title":"Ophthalmology"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223001962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223001962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:24:24Z","timestamp":1759274664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223001962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0190962223001962"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.01.043","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical management of ocular surface disease in patients with atopic dermatitis, with a focus on conjunctivitis: A review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.01.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}